Open-label, multi-centre, proof of concept phase IIa clinical trial on the efficacy and tolerability of an 8 week oral treatment with once daily 9 mg budesonide in patients with active ulcerative colitis
Phase of Trial: Phase II
Latest Information Update: 15 Jun 2017
At a glance
- Drugs Budesonide (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Dr Falk Pharma
- 15 Jun 2017 This trial is completed in Latvia (end date: 20 Feb 2017).
- 01 Jun 2017 This trial is completed in Hungary (End date: 20 Feb 2017).
- 30 Mar 2017 This trial is completed in Lithuania (End date: 20 Feb 2017), according to Eudra record.